PILOT — Private preview. Progress is saved for this browser session only.
HaiPhai.AI Fluency for Biotech

Generative Design: Hypothesis-Driven Molecular Generation

Lesson 3~15 min2-question check

Generative Design: Hypothesis-Driven Molecular Generation

Classical drug discovery starts with a compound (natural product, known drug, screening hit) and optimizes it. Generative chemistry starts with the desired properties and asks: what molecules have those properties? This is a fundamentally different design philosophy, and AI has made it practically executable.

What generative models do

A generative molecular design model is trained on large datasets of compounds with known properties. Given a set of desired property constraints — IC50 < 100 nM, logP < 3, MW < 450, CYP3A4 non-inhibitor — the model generates novel molecules predicted to satisfy those constraints.

The output is not a single compound but a diverse set of candidate molecules, each with:

  • Predicted activity against the target
  • Predicted ADMET properties
  • Synthetic accessibility score (is this actually makeable?)
  • Novelty score (is this sufficiently different from what you already have?)

The design-make-test cycle with generative AI

Traditional design-make-test cycles operate in batches of 20-50 compounds, with 2-4 cycles per year. The generative model changes this:

Cycle 1: Generate 1,000 virtual candidates. Computationally filter to 50 high-probability hits. Synthesize and test.

Cycle 2: Feed test results back into the model. Generate 1,000 more candidates conditioned on the observed activity data. Computationally filter to 50. Synthesize and test.

Cycle 3+: Repeat. The model improves with each cycle as it learns from real experimental data.

The advantage is not that the model is always right — it isn't. The advantage is that by filtering thousands of virtual candidates computationally, you focus synthesis and testing resources on higher-probability compounds, improving the hit rate per synthesis cycle.

Practical constraints

Generative models require computational infrastructure and expertise to deploy well. The synthetic accessibility predictor matters enormously — a model that generates synthetically intractable compounds is generating lab burden, not leads. And experimental validation remains essential: models predict properties but chemistry makes no guarantees.

The right frame: generative design is a hypothesis generation engine. The hypothesis testing remains in the lab.

Knowledge check

2 questions · select an answer to see if you got it
1.What is the fundamental difference between classical drug optimization and generative molecular design?
2.Why does the synthetic accessibility score matter in evaluating generative model output?
Ready to apply this?
Practice with AI →

Bring a real challenge from your work — the AI will help you apply what you just learned.